Everstack Evidence

BB Good human data, but mixed outcomes or surrogate markers. How we grade →Evidence grade · Last reviewed

Omega-3 dose and form: how much EPA and DHA, and does triglyceride vs ethyl ester matter?

Bottom line: Omega-3 EPA and DHA have Grade B evidence on triglycerides and absorption: trials of 4 g a day prescription products lowered very high triglycerides in patients, and doses above 1 g a day showed a small atrial fibrillation signal.

The strongest finding is triglyceride lowering: at prescription doses of 4 g a day (more than 3 g of EPA plus DHA), triglycerides fall by 30% or more in people with very high levels, and EPA-only and EPA plus DHA products lower them by similar amounts (American Heart Association advisory, Skulas-Ray 2019). Absorption studies agree that ethyl esters are absorbed less well than triglyceride forms, mostly when taken without a fatty meal. Heart outcome trials are mixed by dose, form, population and placebo, and doses above 1 g a day carry a small atrial fibrillation signal. Grade B.

Published Sources checked 13 sourcesEverstack research teamHow we work

Reviewed . We sell some of what we grade.

A plated salmon fillet with zucchini, a dietary source of EPA and DHA
A plated salmon fillet with zucchini, a dietary source of EPA and DHA. Photo: Casey Lee, CC0 1.0

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.

The question
How much EPA plus DHA did the human trials actually use compared with a typical fish oil capsule, does the chemical form (natural or re-esterified triglyceride versus ethyl ester) change absorption with and without a fatty meal, and what do REDUCE-IT, STRENGTH and VITAL say about high doses?
Study design
Typical capsule: NIH's Office of Dietary Supplements says a common 1,000 mg fish oil softgel provides about 180 mg EPA and 120 mg DHA, though products vary widely. Dose: the American Heart Association science advisory on 4 g a day of prescription omega-3 for high triglycerides (Skulas-Ray 2019). Form and absorption: two single-dose studies in men comparing fish oil as triglycerides, free fatty acids or ethyl esters, first with a low-fat meal and then with a high-fat meal of 44 g fat (Lawson and Hughes 1988); a 2-week trial in 72 volunteers taking about 3.3 g a day of EPA plus DHA as ethyl esters, free fatty acids, re-esterified triglycerides, natural fish oil or cod liver oil (Dyerberg 2010); a 6-month double-blind trial in 150 volunteers taking 1.68 g a day of EPA plus DHA as re-esterified triglycerides or ethyl esters, or corn oil (Neubronner 2011); and ECLIPSE, a 4-way crossover in 54 overweight adults comparing single 4 g doses of a free fatty acid drug (Epanova) and an ethyl ester drug (Lovaza) on low-fat and high-fat diets (Davidson 2012). Outcomes: VITAL, 25,871 US adults taking a 1 g capsule with 840 mg EPA plus DHA or placebo for a median 5.3 years (Manson 2019); REDUCE-IT, 8,179 statin-treated patients with cardiovascular disease, or diabetes plus other risk factors, and triglycerides of 135 to 499 mg/dL, taking 4 g a day of icosapent ethyl (a purified EPA ethyl ester) or a mineral oil placebo for a median 4.9 years (Bhatt 2019); STRENGTH, 13,078 statin-treated high-risk patients taking 4 g a day of omega-3 carboxylic acids (EPA plus DHA, the Epanova drug) or corn oil (Nicholls 2020); a REDUCE-IT biomarker substudy of the mineral oil comparator (Ridker 2022); and a meta-analysis of atrial fibrillation in 7 cardiovascular outcome trials with 81,210 patients (Gencer 2021). [1][2][3][4][5][6][7][8][9][10][11][12][13]
What they found
The dose gap is large. VITAL's capsule gave 840 mg of EPA plus DHA a day, while REDUCE-IT and STRENGTH gave 4 g of drug a day; reaching the more than 3 g of EPA plus DHA in those doses would take about 10 or more typical 1,000 mg fish oil softgels. Triglycerides: the AHA advisory reports that 4 g a day of EPA plus DHA lowers very high triglycerides by 30% or more, that EPA-only and EPA plus DHA products appear roughly comparable for lowering moderately high triglycerides, and that in that range neither raises LDL cholesterol alone or with a statin. Form: with a low-fat meal, Lawson and Hughes found EPA and DHA from ethyl esters were absorbed only about 20% as well as from free fatty acids, compared with 68% (EPA) and 57% (DHA) for triglycerides; with a high-fat meal, ethyl ester absorption roughly tripled to about 60%, and EPA absorption from triglycerides rose from 69% to 90%. Dyerberg 2010 found re-esterified triglycerides 124% and ethyl esters 73% as bioavailable as natural fish oil. Neubronner 2011 found the Omega-3 Index rose faster and higher with re-esterified triglycerides than with ethyl esters at the same dose (to 197% versus 171% of baseline at 6 months). In ECLIPSE, EPA plus DHA exposure was 4.0 times higher with the free fatty acid drug than with the ethyl ester drug on a low-fat diet, and about 1.3 times higher on a high-fat diet. Outcomes: in REDUCE-IT, the primary event rate was 17.2% with icosapent ethyl versus 22.0% with mineral oil (hazard ratio 0.75, 95% CI 0.68 to 0.83). STRENGTH was stopped early for futility, with 12.0% versus 12.2% (hazard ratio 0.99) and more gastrointestinal side effects on omega-3 (24.7% versus 14.7%). In VITAL, 1 g a day did not lower major cardiovascular events (hazard ratio 0.92, 95% CI 0.80 to 1.06) or invasive cancer; total heart attacks, a secondary outcome, were lower (hazard ratio 0.72), which needs confirmation. In the REDUCE-IT substudy, inflammation markers rose in the mineral oil group (for example, high-sensitivity CRP up 21.9% at 12 months) and barely moved with icosapent ethyl. Atrial fibrillation: across 7 trials, omega-3 was linked to a higher risk of AF (hazard ratio 1.25), more so in trials above 1 g a day (1.49) than at 1 g or less (1.12). STRENGTH saw new AF in 2.2% versus 1.3%, and REDUCE-IT reported more AF hospitalizations (3.1% versus 2.1%). [1][2][3][4][5][6][7][8][9][10][11][12][13]
Limitations
The triglyceride and event trials used prescription drugs at 4 g a day in high-risk patients on statins, not supplements in healthy people, so their results do not transfer to one or two capsules a day. REDUCE-IT tested EPA alone as an ethyl ester and STRENGTH tested EPA plus DHA as carboxylic acids against a different comparator, so the contrast may reflect the molecule, the EPA level reached in blood, the population or the placebo. The mineral oil debate is unresolved: NIH's fact sheet says mineral oil is not a neutral placebo and that the REDUCE-IT gap would likely have been smaller with a more neutral oil, while the Ridker substudy authors called the effect on the event results uncertain. Corn oil is not perfectly inert either. VITAL tested one moderate dose in a mostly healthy population with few events, and its heart attack result was secondary. Form studies are small (8 to 150 people) and short, and they measure blood levels, not health outcomes; Lawson and Hughes compared their high-fat meal results with earlier low-fat data rather than in a same-day crossover. Absorption gaps narrow when omega-3 is taken with a meal that contains fat. AF data in Gencer 2021 came mostly from non-adjudicated reports in older, higher-risk adults. Funding: REDUCE-IT was funded by Amarin Pharma, maker of icosapent ethyl. STRENGTH was funded by AstraZeneca, which took part in designing the study. VITAL was funded by NIH grants, with Omacor fish oil and matching placebo donated by Pronova BioPharma and BASF, and vitamin D donated by Pharmavite. Funding for the absorption studies was not stated in the abstracts we read, and ECLIPSE compared two branded drugs.
What this does not mean
These studies do not show that an omega-3 supplement treats or lowers the risk of heart disease, heart attacks, stroke or any disease. The event results above come from prescription drugs in patients, not from our product. Our claim is structure/function only: EPA and DHA support healthy triglyceride levels already within the normal range. Test before you supplement: a standard lipid panel shows your triglycerides, and an Omega-3 Index blood test shows how much EPA and DHA is in your red blood cells (see our omega-3-index summary). If your triglycerides are high, talk with a clinician; prescription omega-3 is a medical decision, not a supplement dose. Eating oily fish about twice a week does much of the same job. If you buy a capsule, check the label for milligrams of EPA plus DHA per serving, not fish oil per softgel, and take it with a meal that contains some fat. Safety: NIH's Office of Dietary Supplements notes that fish oil can have antiplatelet effects at high doses and that people taking warfarin or similar anticoagulants should discuss it with their clinician; prescription omega-3 labels advise periodic INR checks with anticoagulants. In trials, doses above 1 g a day were linked to more atrial fibrillation, so people with AF or palpitations should ask a clinician first. If you have a fish or shellfish allergy, check the oil source and ask your allergist before taking fish oil. Common side effects are mild: unpleasant taste, bad breath, heartburn, nausea and diarrhea. FDA and the European Food Safety Authority consider up to about 5 g a day of EPA plus DHA safe for adults. For the heart outcome trials in more depth, see omega-3-heart-outcomes.
Sources
  1. Skulas-Ray AC et al. Circulation. 2019;140(12):e673-e691. AHA science advisory on triglycerides. doi.org/10.1161/CIR.0000000000000709 Our summary: Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
  2. Lawson LD, Hughes BG. Biochem Biophys Res Commun. 1988;152(1):328-335. Absorption by form, low-fat meal. doi.org/10.1016/s0006-291x(88)80718-6 Our summary: Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters
  3. Lawson LD, Hughes BG. Biochem Biophys Res Commun. 1988;156(2):960-963. Absorption with a high-fat meal. doi.org/10.1016/s0006-291x(88)80937-9 Our summary: Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal
  4. Dyerberg J et al. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137-141. Bioavailability of formulations. doi.org/10.1016/j.plefa.2010.06.007 Our summary: Bioavailability of marine n-3 fatty acid formulations
  5. Neubronner J et al. Eur J Clin Nutr. 2011;65(2):247-254. Omega-3 Index, re-esterified triglyceride vs ethyl ester. doi.org/10.1038/ejcn.2010.239 Our summary: Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters
  6. Davidson MH et al. J Clin Lipidol. 2012;6(6):573-584. ECLIPSE, free fatty acid vs ethyl ester. doi.org/10.1016/j.jacl.2012.01.002 Our summary: A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study
  7. Bhatt DL et al. N Engl J Med. 2019;380(1):11-22. REDUCE-IT. doi.org/10.1056/NEJMoa1812792 Our summary: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
  8. Nicholls SJ et al. JAMA. 2020;324(22):2268-2280. STRENGTH. doi.org/10.1001/jama.2020.22258 Our summary: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
  9. Ridker PM et al. Circulation. 2022;146(5):372-379. REDUCE-IT mineral oil biomarker substudy. doi.org/10.1161/CIRCULATIONAHA.122.059410 Our summary: Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
  10. Manson JE et al. N Engl J Med. 2019;380(1):23-32. VITAL. doi.org/10.1056/NEJMoa1811403 Our summary: Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
  11. Gencer B et al. Circulation. 2021;144(25):1981-1990. Atrial fibrillation meta-analysis. doi.org/10.1161/CIRCULATIONAHA.121.055654 Our summary: Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
  12. Harris WS, von Schacky C. Prev Med. 2004;39(1):212-220. The Omega-3 Index. doi.org/10.1016/j.ypmed.2004.02.030 Our summary: The Omega-3 Index: a new risk factor for death from coronary heart disease?
  13. NIH Office of Dietary Supplements: Omega-3 Fatty Acids fact sheet for health professionals (updated 22 Aug 2025). ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/

Why people take it

One row per claim you are likely to hear, each graded on its own. We never average them into one score.

This grade rates the published evidence for this molecule for this use. It does not rate our product, its quality or its testing.

A low grade doesn't mean the molecule is harmful or that you should stop taking it. It means the human evidence for that use is thin. Whether to take it is your call; our job is to show you what the studies found. This is not medical advice.

BB Good human data, but mixed outcomes or surrogate markers. How we grade →

Maintaining healthy triglyceride levels: Grade B

Human trialsThe use on our label.

Why this grade. The most consistent finding: at prescription doses of about 4 g a day, EPA and DHA lower very high triglycerides by 30% or more (American Heart Association advisory). Our capsule dose is far lower than that.

DD Mostly mechanistic or early data. Shown openly. How we grade →

A higher Omega-3 Index and longer life: Grade D

MixedNot a claim we make for our product.

Why this grade. Cohorts link a higher index with lower death rates (in Framingham, 34% lower in the top fifth), but cohorts cannot show cause. In the VITAL trial, 1 g a day did not change death from any cause, and no trial has tested whether raising the index lengthens life.

Where people hear it
BB Good human data, but mixed outcomes or surrogate markers. How we grade →

Resting blood pressure: Grade B

MixedNot a claim we make for our product.

Why this grade. A dose-response meta-analysis of 4973 people found systolic pressure 2.61 mm Hg lower at 2 g a day and at 3 g a day of EPA plus DHA, with a stronger relation in people with hypertension. A Cochrane review of trials lasting at least 12 months found little or no effect on blood pressure. In 2157 adults aged 70 or older, 1 g a day for 3 years left systolic pressure 0.8 mm Hg lower, and that difference was not statistically significant.

CC Small or few human trials. Promising, not proven. How we grade →

DNA methylation clocks in a post hoc analysis of adults 70 and older: Grade C

Human trialsNot a claim we make for our product.

Why this grade. One post hoc analysis of 777 adults aged 70 and older found that 1 g a day of omega-3 for 3 years slowed three DNA methylation clocks by 2.9 to 3.8 months. The authors called this a small effect on surrogate clocks. The same trial's main results, in 2157 adults, found no statistically significant difference in physical performance, a cognition score, fractures, infections, or blood pressure. This is one post hoc analysis, not a measure of longer life.

AA Multiple randomized trials or meta-analyses, consistent results. How we grade →

EPA and DHA status: Grade A

Human trialsNot a claim we make for our product.

Why this grade. Supplementation raises EPA and DHA in red blood cells, the Omega-3 Index, in a dose-dependent way. In 115 healthy adults, dose alone explained about 68% of the change over about 5 months, and a pool of 14 trials (1,422 people) found the index rose from 4.9% to 8.1% at a mean of about 2 g a day. A model from that pool predicted that 850 mg a day as ethyl esters would take a starting index of 4.9% to about 6.5%.

CC Small or few human trials. Promising, not proven. How we grade →

Muscle strength and lean mass: Grade C

MixedNot a claim we make for our product.

Why this grade. Reviews in healthy adults do not show a clear gain in muscle mass. A review of 14 trials (1,443 people) found only a very small strength effect and rated the trials at high risk of bias, while a review in adults 55 and older reported better lower-body strength but no more lean mass. A 6-month trial that 44 people finished found a 3.6% rise in thigh muscle volume, so the signal is promising, not proven.

Quoted for accuracy. No one quoted here endorses Everstack, is affiliated with us or is paid by us. A famous name never raises a grade. All claims we track · Grade change log

Common questions

How much omega-3 should I take a day?

Read the milligrams of EPA plus DHA on the label, not the total fish oil per softgel. The large triglyceride reductions come from prescription products at 4 g a day in patients with high triglycerides. That dose is a medical decision, and those results do not show the same effect from one or two ordinary capsules or from eating fish.

Should I take omega-3 with food?

Yes, with a meal that contains some fat. In absorption studies, ethyl-ester fish oil was absorbed about three times better with a high-fat meal than with a low-fat one (Lawson 1988).

What is omega-3 good for?

Its best-shown effect is on triglycerides (grade B): at prescription doses of 4 g a day, they fell by 30% or more in people with very high levels. That is a medical decision, not a supplement dose; if your triglycerides are high, talk with a clinician. Heart outcome trials are mixed.

Related summaries

Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.